Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
SI-BONE, Inc. reports developments for a medical device business focused on procedural solutions for compromised bone and sacropelvic disorders. The company develops technologies centered on spinopelvic anatomy, including applications in minimally invasive SI joint fusion, adult spinal deformity, spinopelvic and sacropelvic fixation, and pelvic trauma.
Recurring updates include quarterly and annual financial results, revenue guidance, cash flow and adjusted EBITDA commentary, physician adoption metrics, reimbursement developments, and healthcare conference presentations. Product references include the iFuse Implant System, iFuse Bedrock Granite, iFuse TORQ, iFuse TORQ TNT, iFuse 3D, and related surgical implant technologies.
SANTA CLARA, Calif., Jan. 9, 2023 — SI-BONE, Inc. (NASDAQ: SIBN) announced preliminary fourth quarter and fiscal year 2022 revenue. Fourth quarter revenue is expected between $31.7 and $31.9 million, a 26% increase year-over-year. U.S. revenue is projected at $29.8 to $29.9 million, up 28%. For 2022, worldwide revenue is anticipated between $106.1 and $106.3 million, reflecting an 18% increase. Cash and marketable securities are forecasted at $96 million as of December 31, 2022.
SI-BONE, Inc. (NASDAQ: SIBN) announced its participation in the 25th Annual Needham Growth Conference, set for January 12, 2023, at 11:45 a.m. ET. Management will host a virtual fireside chat during this event.
A live webcast will be accessible on the company’s website, with recordings available for at least 90 days afterward. SI-BONE specializes in surgical treatments for musculoskeletal disorders, notably the iFuse Implant System. Since its introduction in 2009, over 75,000 procedures have been performed, supported by extensive clinical research.
SI-BONE, Inc. (Nasdaq: SIBN) announced FDA clearance for iFuse Bedrock Granite, now indicated for use with various pedicle screw rods. This implant, introduced in May 2022, helps address complications in adult spinal deformity treatments, improving surgical outcomes. The expanded clearance allows surgeons to use preferred techniques while enhancing treatment options. CEO Laura Francis believes this will increase surgeon adoption of the device. Since its launch, iFuse has been a favored implant in pelvic fixation constructs.
SI-BONE, a medical device company, reported Q3 2022 revenue of $26.4 million, a 19% increase year-over-year. U.S. revenue reached $24.6 million, a 21% increase, while international revenue decreased by 5% to $1.8 million.
Gross margin stood at 84%, down from 89% a year earlier, impacted by pricing and cost factors. Operating expenses rose 9% to $35.8 million, leading to an operating loss of $13.6 million. The company maintains a revenue guidance of $104 million to $105 million for 2022, reflecting a growth rate of 16% to 17%.
SI-BONE, Inc. (Nasdaq: SIBN) announced it will release its third-quarter 2022 financial results on November 7, 2022, post-market close. A conference call will follow at 1:30 PM PT / 4:30 PM ET, allowing investors to engage in a discussion regarding the results. SI-BONE is recognized for its iFuse Implant System aimed at treating sacropelvic disorders, with over 70,000 procedures performed by more than 2,800 surgeons. The company has established a strong reimbursement advantage, supporting its market leadership in minimally invasive surgical solutions.
SI-BONE, Inc. (NASDAQ: SIBN), a leader in surgical solutions for sacropelvic disorders, announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference. Management will hold a fireside chat on September 14, 2022, at 8:00 a.m. Eastern Time. A live webcast and an archived recording will be available on the company’s website for 90 days post-event. SI-BONE has pioneered the iFuse Implant System since 2009, enabling over 70,000 minimally invasive SI joint fusion procedures, supported by extensive clinical evidence and universal insurance coverage.
SI-BONE, Inc. (Nasdaq:SIBN) reported record worldwide revenue of $25.6 million for Q2 2022, an increase of 15% year-over-year. U.S. revenue of $23.8 million grew 18%, while international revenue fell 8% to $1.8 million. The gross margin was 86%, down from 89% the previous year, attributed to lower average selling prices and rising operational costs. Operating expenses surged 22% to $40.0 million, leading to a net loss of $18.5 million or $0.54 per diluted share. The company anticipates 2022 revenue between $106 million and $108 million.
SI-BONE, Inc. (Nasdaq: SIBN), a leader in surgical solutions for musculoskeletal disorders, announced that CEO Laura Francis and CFO Anshul Maheshwari will present at the Canaccord Genuity 42nd Annual Growth Conference in Boston. The live webcast is scheduled for August 10, 2022, at 9:00 AM ET and will be available for replay on the company's investor relations website for at least 90 days. SI-BONE's iFuse Implant System is used in treating SI joint pain, with over 65,000 procedures performed.
SI-BONE, Inc. (Nasdaq: SIBN), a leader in treating musculoskeletal disorders, will announce its second-quarter 2022 financial results on August 8, 2022, post-market. A live conference call will follow at 1:30 PM PT/4:30 PM ET, accessible by phone or via webcast on their website. The company, known for its iFuse Implant System, has established a robust market presence with over 65,000 procedures performed. Their proprietary reimbursement advantage underscores their market leadership in surgical treatments for sacropelvic issues.
SI-BONE, Inc. (SIBN) announced FDA clearance for the iFuse-TORQ system for pelvic fracture fixation, including acute and non-acute fractures. This approval expands the treatment of pelvic fragility and insufficiency fractures, addressing a market opportunity of approximately $300 million. With 120,000 such fractures occurring annually in the U.S., this innovation is aimed at reducing the complications associated with traditional treatment methods. The iFuse-TORQ is positioned to help remobilize patients suffering from these debilitating injuries.